Navigation Links
Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Date:11/1/2012

TITUSVILLE, N.J., Nov. 1, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV). The regimen will include Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue HCV polymerase inhibitor VX-135. As a first step, Janssen will conduct a drug-drug interaction (DDI) study with simeprevir and VX-135. The DDI study will support the initiation of the Phase 2 study in early 2013 pending discussions with regulatory authorities.

The goal of the Phase 2 study will be to evaluate the safety, tolerability and viral cure rates of a 12-week regimen of simeprevir and VX-135, administered with and without ribavirin, in treatment-naive patients who have chronic non-cirrhotic genotype 1 HCV. The companies will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.

Simeprevir is an investigational NS3/4A protease inhibitor currently in Phase 3 trials, developed in collaboration with and licensed from Medivir AB. VX-135 is an investigational uridine nucleotide analogue pro-drug designed to inhibit the replication of HCV by acting on the NS5B polymerase. 

"There is a significant unmet need for all-oral treatment regimens for people living with hepatitis C," said Wim Parys, Global Head of Infectious Diseases at Janssen. "Janssen's collaboration with Vertex underscores our commitment to better understand the potential utility of simeprevir in a number of different interferon-free treatment combinations and HCV patient populations."

About Simeprevir
Simeprevir (TMC435) is an NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB to treat chronic HCV infection. Simepr
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. Watson Announces Global Generics Management Team
8. Watson Announces New Name -- Actavis -- for Global Operations
9. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... UNION CITY, Calif. , Oct. 1, 2014 /PRNewswire/ ... products company manufacturing point-of-care instruments and consumables for the ... lab services to the veterinary and research markets in ... it has entered into a definitive distribution agreement with ... inventory, market and promote the full line of Abaxis ...
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)... , Oct. 1, 2014   Plexus Information ... of Anesthesia Information Management Systems (AIMS), announced a ... , a wholly owned subsidiary of Quality Systems, ... systems and connectivity solutions.  Logo ... This partnership extends the ...
Breaking Medicine Technology:Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Cardinal Health 2014 Digital Report to Shareholders Now Available 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... A leading Internet pharmacy verification service offers a ... affordable medicines without using unregulated, potentially dangerous "rogue" Internet ... "rogue" Internet pharmacies and verifies legitimate ones, now offers ... cannot afford their medicines to find patient assistance programs ...
... 2010 Ambit Biosciences Corporation (“Ambit”), announced today that it ... Commission ("SEC") relating to the proposed initial public offering of ... be offered and the price range for the offering have ... to be sold in the offering will be offered by ...
Cached Medicine Technology:Need Help Affording Your Meds? LegitScript Adds Patient Assistance Feature 2Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering 2
(Date:10/1/2014)... (PRWEB) October 01, 2014 Join the more ... Eating Disorder Treatment Center’s first ever charity golf tournament to ... people with eating disorders who cannot afford treatment. The tournament ... Club in Eureka, Mo. , The day-long event starts ... A reception and award dinner will begin at 5 p.m. ...
(Date:10/1/2014)... Beverly Hills, California (PRWEB) October 01, 2014 ... relationship expert, Dr. Kathleen Mojas is celebrating 20 years ... she has assisted hundreds of people to achieve greater ... released an important list of warning signs and suggestions ... relationship. , Dr. Mojas explains: “Believe it or ...
(Date:10/1/2014)... Innovations announces the upcoming airing of ... Monday, October 20, 2014 at 7:30 a.m. EST/PT via ... behind the scenes to learn about Break the Cycle’s ... the practical help and information Break the Cycle provides ... signs of abuse, how to navigate the legal system, ...
(Date:10/1/2014)... October 01, 2014 NoteSwift Inc., announced ... versions 10.0, 12.1 and 13.0. NoteSwift is the bridge ... commands to navigate and document clinical information at the ... spends creating a patient note by more than half ... the major pain points providers state impedes EHR use ...
(Date:10/1/2014)... 01, 2014 Scientists at the University ... that target immune system proteins has the power to ... posted details of the new study on their website. ... , Researchers in the UWA School of Pathology and ... to mice with mesothelioma with promising results. , ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... it may be better than standard oxygen therapy, study suggests ... that a mechanical ventilator can ease suffering and help lung ... A large percentage of these patients didn,t want to have ... wear an oxygen mask. But those who were willing to ...
... in Fight Against Tobacco Recognized Nationally-, WASHINGTON, May ... the Central Regional Youth Advocate of the Year,by the ... fight,against tobacco. Michelle is being honored at a gala ... national winner, international grant winner,three other regional winners and ...
... is Possible!, DETROIT, Mich., May 19 Patrick Hendry ... of bipolar disorder.,He spent seven years in and out of ... went so far as trying,electro-convulsive therapy, similar to shock therapy., ... my life. You feel,hopeless and lost," said Hendry. "It,s difficult ...
... WASHINGTON, May 20 Auriel Rolle-Polk, 17, of,Tallahassee, FL ... the,Year by the Campaign for Tobacco-Free Kids for her ... at a gala in the nation,s capital,on May 20 ... regional winners and a group winner., Auriel, a ...
... 20 Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ... its fourth quarter and fiscal year 2008 ended ... Thursday May 29, 2008., Detroit-based Caraco Pharmaceutical ... private-label,pharmaceuticals to the nation,s largest wholesalers, distributors,drugstore chains ...
... Ischemic injury to the bowel is a well known disease ... findings. A sudden drop in the colonic blood supply is ... of macrovascular mesenteric vein rarely causes ischemia of the bowel. ... by obstruction of the mesenteric and splenic veins. , ...
Cached Medicine News:Health News:Ventilator Relieves Lung Cancer Pain in Final Hours 2Health News:Ventilator Relieves Lung Cancer Pain in Final Hours 3Health News:Campaign for Tobacco-Free Kids Honors Michelle Mays of Rhinelander, WI As Youth Advocate of the Year 2Health News:Man who Lost Everything Comes to Detroit to Spread Message of Hope 2Health News:Campaign for Tobacco-Free Kids Honors Auriel Rolle-Polk of Tallahassee, FL As Youth Advocate of the Year 2Health News:Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: